PHP
TRIL

Parkman Healthcare Partners’s Trillium Therapeutics Inc. TRIL Stock Holding History

Parkman Healthcare Partners’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-211,385
Closed -$2.05M – 92
2021
Q2 		$2.05M Buy
211,385
+61,081
+41% +$575K 0.45% 56
2021
Q1 		$1.61M Sell
150,304
-14,281
-9% -$177K 0.37% 61
2020
Q4 		$2.42M Sell
164,585
-210,478
-56% -$3.04M 0.62% 54
2020
Q3 		$5.33M Buy
375,063
+75,063
+25% +$748K 1.41% 28
2020
Q2 		$2.43M Sell
300,000
-125,000
-29% -$773K 0.68% 50
2020
Q1 		$1.72M Buy
+425,000
New +$1.61M 0.8% 42

Other funds holding TRIL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
VI
Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return

Parkman Healthcare Partners's TRIL Position: Q3 2021 in Review

Parkman Healthcare Partners sold out of Trillium Therapeutics Inc. (TRIL) in Q3 2021, closing a stake of 211,385 shares — an estimated $2.05M sold.

Parkman Healthcare Partners first reported a position in TRIL in Q1 2020 and held it in 6 quarters. The position peaked at $5.33M in Q3 2020. 182 funds tracked by Wall St. Rank hold TRIL as of Q3 2021.

  • Parkman Healthcare Partners reported no remaining Trillium Therapeutics Inc. position as of Q3 2021 after selling out during the quarter.
  • Parkman Healthcare Partners sold 211,385 Trillium Therapeutics Inc. shares in Q3 2021, an estimated $2.05M.
  • Parkman Healthcare Partners first reported a position in Trillium Therapeutics Inc. in Q1 2020 and held it in 6 quarters.
  • Parkman Healthcare Partners's Trillium Therapeutics Inc. position peaked at $5.33M in Q3 2020.
  • 182 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2021.

Based on Parkman Healthcare Partners's 13F filing for Q3 2021, filed 12 Nov 2021.